Bing Li | Endocarditis | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Dr. Bing Li | Endocarditis | Best Researcher Award

Dr. Bing Li, Chinese PLA General Hospital First Medical Center, China

Dr. Bing Li is an Associate Chief Physician at The First Medical Center, Chinese PLA General Hospital, Beijing, China. He holds a Ph.D. in Endocrinology and Metabolism from PLA Medical College (2020) and has a Master’s Degree (2013) in the same field. His expertise includes diabetes, thyroid disorders, metabolic syndrome, and endocrine diseases. Dr. Li is actively involved in clinical practice, research, and medical education, contributing to advanced treatments and diagnostic techniques. His work has been published in leading medical journals, making a significant impact on endocrinology and metabolic disease management in China.

AUTHOR PROFILE

Scopus Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Bing Li’s academic journey began with a Bachelor’s Degree in Clinical Medicine from Hebei Medical University (2005–2010), where he laid the foundation for his expertise in the medical field. His passion for endocrinology and metabolism led him to pursue a Master’s Degree at PLA Medical College (2010–2013), further deepening his understanding of metabolic disorders and endocrine health. His dedication culminated in a Ph.D. in Endocrinology and Metabolism (2016–2020), where he focused on advanced research in hormonal and metabolic diseases.

🏥PROFESSIONAL ENDEAVORS:

Currently serving as an Associate Chief Physician at The First Medical Center, Chinese PLA General Hospital, Beijing, Dr. Li plays a crucial role in treating and managing complex endocrine disorders. His expertise spans diabetes, thyroid diseases, adrenal disorders, and metabolic syndromes, making him a key figure in China’s medical landscape.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON ENDOCARDITIS:

Dr. Li’s research primarily revolves around:

  • Diabetes and Insulin Resistance 🩸
  • Thyroid Disorders and Hormonal Imbalances 🦋
  • Adrenal and Pituitary Gland Diseases 🔄
  • Metabolic Syndrome and Obesity-Related Conditions ⚖️

His work aims to improve diagnostic techniques, enhance treatment protocols, and develop innovative therapeutic strategies for endocrine disorders. Through his research, he has contributed to clinical advancements in the management of metabolic diseases.

🌍IMPACT AND INFLUENCE:

Dr. Bing Li has made significant contributions to the Chinese medical community, particularly in endocrinology and metabolic medicine. As an Associate Chief Physician, he has influenced:

  • Clinical practices by integrating research-based solutions
  • Medical education through mentoring young doctors and researchers
  • Public health awareness on diabetes prevention and treatment

His work has helped shape medical guidelines and policies, ensuring improved patient outcomes in China and beyond.

📚ACADEMIC CITATIONS AND RECOGNITION:

Dr. Li’s scientific publications in high-impact medical journals have been widely cited by researchers and clinicians. His studies on endocrine disorders, metabolic regulation, and hormone-related diseases are highly regarded in the medical community.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

With a strong foundation in endocrinology, Dr. Bing Li is set to expand his influence in medical research, clinical innovation, and public health policy. His future endeavors may include:
✅ Leading cutting-edge research in precision medicine for endocrine disorders
✅ Collaborating on international studies to enhance metabolic disease treatment
✅ Developing new medical technologies for early diagnosis and personalized therapy

Dr. Li’s dedication to medical excellence ensures that his legacy in endocrinology will continue to impact future generations of physicians and researchers.

🚀CONCLUSION:

Dr. Bing Li’s dedication to endocrinology and metabolic research has significantly impacted clinical practice, medical education, and patient care. His expertise in diabetes, thyroid disorders, and metabolic diseases continues to shape advanced treatments and innovative diagnostic approaches. As an Associate Chief Physician, he plays a vital role in improving healthcare outcomes in China. With his commitment to scientific progress and medical excellence, Dr. Li’s influence will extend to future generations of physicians and researchers. His work ensures better disease management, improved therapies, and enhanced patient well-being for years to come.

TOP NOTABLE PUBLICATIONS

Association Between Skin Autofluorescence and Coronary Heart Disease in Chinese General Population: A Cross-Sectional Study

Authors: Qingzheng Wu, Yu Cheng, Hongyan Liu, Bing Li, Yiming Mu

Journal: Journal of Diabetes

Year: 2025

The Efficacy and Safety of iGlarLixi versus IDegAsp in Chinese Patients with Type 2 Diabetes Suboptimally Controlled with Oral Antidiabetic Drugs: Interpretation of the Soli-D Study

Authors: Ming Liu, Weijun Gu, Li Chen, Yanbing Li, Hongyu Kuang, Jianling Du, Agustina Alvarez, Felipe Lauand, Elisabeth Souhami, Jiewen Zhang, Weiya Xu, Qin Du, Yiming Mu

Journal: Diabetes, Obesity & Metabolism

Year: 2024

Christina Antza | Hypertension | Best Research Article Award

Posted on by Cardiology and Cardiovascular Medicine

Assist. Prof. Dr. Christina Antza | Hypertension | Best Research Article Award

Assist. Prof. Dr. Christina Antza, 3rd Department of Internal Medicine, Aristotle University of Thessaloniki, Greece

Assist. Prof. Dr. Christina Antza is a specialist in Internal Medicine and Hypertension at the 3rd Department of Internal Medicine, Aristotle University of Thessaloniki, Greece. She holds an M.D., a Ph.D. in blood pressure measurement methods, and an M.Sc. in Research Methodology. Dr. Antza has extensive experience in hypertension, metabolic syndrome, diabetes, and atherosclerosis. She has worked as a researcher, consultant, and medical educator in Greece and the UK. Recognized with multiple awards and fellowships, she actively contributes to international medical research and education, shaping advancements in cardiovascular and metabolic disease management.

AUTHOR PROFILE

Orcid Profile

🎓 EARLY ACADEMIC PURSUITS:

Dr. Christina Antza began her educational journey at the Fifth High-School of Drama (Junior High School) and Third High School of Drama (Senior High School). She then pursued her Medical Degree at Aristotle University of Thessaloniki, Greece (2007-2013), graduating with an impressive 8/10 grade.

Her passion for research and academia led her to further studies, including:

  • Ph.D. in Internal Medicine (2014-2019) – Focused on blood pressure measurement methods and their ability to predict early vascular aging. She earned a Grade A with Distinction under the supervision of Prof. V. Kotsis.
  • Master of Science in Research Methodology in Medicine and Health Science (2016-2018) – Achieved an outstanding 9/10 grade.
  • Research Fellowship (2019-2020) – Conducted clinical and research work in Diabetes Mellitus and Obesity at the University of Birmingham, UK.
  • Postdoctoral Research (2019-2022) – Specialized in Hypertension and Metabolic Syndrome at Aristotle University of Thessaloniki.
  • Internal Medicine Consultant Certification (2021) – Earned after passing rigorous written and oral examinations.

💼 PROFESSIONAL ENDEAVORS:

Dr. Antza has held various prestigious roles in internal medicine, focusing on hypertension, metabolic syndrome, and endocrinology:

  • Scientific Associate (2013-2014) – Engaged in research and clinical practice in hypertension at the 3rd Department of Internal Medicine, Aristotle University of Thessaloniki.
  • Medical Resident (2016-2021) – Trained at Papageorgiou General Hospital, Aristotle University of Thessaloniki.
  • Academic Fellowship in Hypertension & Metabolic Syndrome (2021-2022) – Focused on clinical practice, independent teaching, and research.
  • Internal Medicine Consultant (2021-2023) – Served at Papageorgiou General Hospital and Bioclinic, offering expertise in hypertension, diabetes, and emergency medicine.
  • Assistant Professor of Internal Medicine – Hypertension (2023-Present) – Currently educating future medical professionals and leading research at Aristotle University of Thessaloniki.

Additionally, she has participated as a Subinvestigator in Phase 2 & 3 Clinical Trials, contributing to advancements in hypertension and metabolic disorders.

📚 CONTRIBUTIONS AND RESEARCH FOCUS ON HYPERTENSION:

Dr. Antza has extensively researched hypertension, metabolic syndrome, diabetes, lipid disorders, and vascular aging. Her work has focused on:

  • Blood Pressure Measurement Techniques (Home, Ambulatory, and Clinical).
  • Atherosclerosis and Cardiovascular Risk.
  • Metabolic Syndrome and Obesity-Related Disorders.
  • Diabetes and Endocrine Disorders.

She has been actively involved in research collaborations with leading medical institutions, including Queen Elizabeth Hospital, Birmingham, UK, where she served as an Honorary Observer (2019-2022) in the Endocrinology Department.

🏆 IMPACT AND INFLUENCE:

Dr. Antza’s work has been recognized with numerous awards and fellowships:

  • Young Fellow of the European Atherosclerosis Society (2019-Present).
  • Young Fellow of the European Hypertension Society (2023-Present).
  • Recipient of multiple Investigator Grants & Travel Awards from the European Society of Hypertension (ESH) and European Atherosclerosis Society (EAS).
  • 1st Place Oral Presentation Award – 8th Panhellenic Congress of the Hellenic Atherosclerosis Society (2019).
  • 2nd Clinical Research Award – 9th Panhellenic Congress of the Hellenic Atherosclerosis Society (2020).
  • Young Investigator Fellowship Award – 89th EAS Virtual Congress (2021).

📖 ACADEMIC CITATIONS & SCHOLARSHIPS:

Dr. Antza’s research has been widely cited in medical literature, influencing clinical guidelines in hypertension and metabolic diseases. Her scholarly excellence has earned her:

  • Ph.D. Scholarship from the Hellenic Society of Atherosclerosis (2014-2015).
  • Postdoctoral Research Scholarship from the State Scholarship Foundation (2019-2021).
  • Award from the Medical Sciences Deanery for Ph.D. Research (2020).

🌍 LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Christina Antza is poised to make significant future contributions in the diagnosis and management of hypertension, metabolic syndrome, and cardiovascular diseases. Her expertise in clinical research, education, and innovative treatment strategies will continue to shape internal medicine and patient care.

Her future goals include:
✔ Expanding research on hypertension-related complications and vascular aging.
✔ Leading international collaborations in cardiovascular and metabolic diseases.
✔ Mentoring the next generation of medical professionals and researchers.
✔ Contributing to global guidelines on hypertension and cardiovascular risk management.

Her dedication to patient care, research, and teaching makes her an influential figure in modern internal medicine and hypertension research.

🌟CONCLUSION :

Assist. Prof. Dr. Christina Antza is a dedicated clinician, researcher, and educator in the fields of hypertension, metabolic syndrome, and internal medicine. With a strong academic foundation, international research collaborations, and numerous accolades, she continues to advance medical knowledge and improve patient care. Her contributions to medical education and research have made a lasting impact, inspiring future generations of physicians. As she progresses in her career, Dr. Antza remains committed to innovation, scientific discovery, and excellence in healthcare, shaping the future of cardiovascular and metabolic disease management. Her work stands as a testament to dedication and expertise.

TOP NOTABLE PUBLICATIONS

Clinic, Ambulatory and Home Blood Pressure Monitoring for Metabolic Syndrome: Time to Change the Definition?

Journal: Medicina

Year: 2025

The Microbial Perspective: A Systematic Literature Review on Hypertension and Gut Microbiota

Journal: Nutrients

Year: 2024

The Effects of Olive Oil Consumption on Biochemical Parameters and Body Mass Index of People with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal: Nutrients

Year: 2024

Familial Hypercholesterolemia in the Elderly: An Analysis of Clinical Profile and Atherosclerotic Cardiovascular Disease Burden from the Hellas-FH Registry

Journal: Biomedicines

Year: 2024

The Modern Environment: The New Secondary Cause of Hypertension?

Journal: Medicina

Year: 2023

The Importance of Out-of-Office Blood Pressure Measurement, as Highlighted by the Correlation with Left Ventricular Hypertrophy in an Untreated Hypertensive Population

Journal: Medicina

Year: 2023

Wei Zhang | Pharmacology | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Mr. Wei Zhang | Pharmacology | Best Researcher Award

Mr. Wei Zhang, Central South University, China

Mr. Wei Zhang is a Professor of Clinical Pharmacology at Central South University, China. He earned his Ph.D. in Pharmacology in 2006 under Prof. Hong-Hao Zhou. With expertise in pharmacogenomics, drug metabolism, and clinical trials, he has led major research projects, including personalized therapy and pharmacogenomic studies in diabetes. Zhang has served as Associate Dean of the Institute of Clinical Pharmacology and has been recognized with prestigious awards like the “New Century Excellent Talents” and “Henry Fok Young Teacher Award.” His research has significantly influenced precision medicine, enhancing drug efficacy and safety through genetic insights.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

🎓EARLY ACADEMIC PURSUITS:

Mr. Wei Zhang embarked on his academic journey at Central South University, China. He demonstrated a strong commitment to pharmacology and clinical medicine from an early stage:

  • Ph.D. in Pharmacology (2003-2006) – Under the supervision of Prof. Hong-Hao Zhou, a distinguished member of the China Engineering Academy, he specialized in clinical pharmacology, drug assay, pharmacokinetics, and pharmacodynamics.
  • M.A. in Pharmacology (2001-2003) – Focused on clinical pharmacology and pharmacogenomics, with practical expertise in human DNA pyrosequencing and drug metabolism.
  • B.A. in Clinical Medicine (1996-2001) – Gained foundational knowledge in pharmacology, physiology, pathology, and clinical medicine at XiangYa Medical School.

🏅PROFESSIONAL ENDEAVORS:

Throughout his career, Mr. Zhang has held significant academic and administrative roles at Central South University, contributing to the advancement of clinical pharmacology:

  • Professor (2013-Present) – Department of Clinical Pharmacology, Central South University.
  • Associate Dean (2009-Present) – Institute of Clinical Pharmacology.
  • Visiting Scholar (2012-2013) – University of Maryland, USA, exploring cutting-edge pharmaceutical research.
  • Head of Genetic Testing Laboratory (2007-2013) – Pioneered pharmacogenomic analysis.
  • Associate Professor (2008-2013) & Lecturer (2006-2008) – Focused on research and teaching in pharmacology.
  • Scientific Secretary (2005-Present) – National Key Discipline of Pharmacology, managing national-level research initiatives.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACOLOGY:

Mr. Zhang has led groundbreaking pharmacogenomics research, focusing on drug metabolism, personalized medicine, and renal drug toxicity. He has been a Principal Investigator (PI) in numerous national projects, including:

  • Pharmacogenomics Research on Type 2 Diabetes (2016-2019) – National Natural Science Foundation of China.
  • Multidrug Resistance Protein 2 (MRP2) & Cisplatin Nephrotoxicity (2013-2015) – Investigating genetic variations affecting renal drug accumulation.
  • Personalized Therapy via Pharmacogenetic Biomarkers (2012-2016) – National High Technology Research & Development Program (863 Program).
  • OATP1B1 Modulators & Mechanisms (2009-2011) – Studied drug transport mechanisms in human liver cells.
  • Pharmacogenomics in Drug Development (2009-2010) – Contributed to the national push for innovative drug research in China.

🌏IMPACT AND INFLUENCE:

As a global thought leader, Mr. Zhang has actively participated in international conferences and academic collaborations, including:

✅ Keynote Speaker & Presenter at pharmacogenetics conferences in China, Korea, Hong Kong, and the USA.
✅ Chairperson at the Cross-Strait Symposium on Pharmacogenomics (2012).
✅ Presenter at AAPS Annual Meeting (2013, USA).
✅ Collaborations with leading global research institutions.

His research has significantly influenced precision medicine and drug safety protocols, enhancing clinical trial methodologies worldwide.

🏆ACADEMIC CITES AND RECOGNITION:

Mr. Zhang’s academic excellence has been recognized through numerous awards and scholarships:

Class I Scholarship, Central South University (2004, 2005).
Outstanding Postgraduate Student Award (2004, 2005).
Excellent Report Award, Chinese Pharmacological Society (2005).
Outstanding Graduate of Central South University (2006).
“New Century Excellent Talents” Award, Ministry of Education (2010).
Science & Technology Prize, Chinese Society of Pharmacy (2010).
China Scholarship Council Foreign Fund (2012).
Outstanding Young Talents Award, China (2013).
Henry Fok Young Teacher Award (2014).

These accolades underscore his significant contributions to pharmacology and clinical research.

🔮LEGACY AND FUTURE CONTRIBUTIONS:

Mr. Zhang’s pioneering research in pharmacogenomics and clinical pharmacology has laid a strong foundation for:

  • Advancements in Personalized Medicine – Tailoring drug therapies based on genetic profiles.
  • Improved Drug Safety & Efficacy – Minimizing adverse drug reactions through genomic insights.
  • Mentorship & Academic Leadership – Training the next generation of pharmacologists and medical researchers.
  • Innovative Drug Development Strategies – Enhancing China’s pharmaceutical industry through precision medicine.

His vision for the future includes expanding global collaborations, leveraging AI in pharmacogenomics, and fostering next-generation clinical trials to revolutionize drug development and patient care.

🌟CONCLUSION:

Mr. Wei Zhang has made remarkable contributions to the field of clinical pharmacology and pharmacogenomics. His extensive research on personalized medicine, drug metabolism, and genetic biomarkers has advanced precision medicine, improving drug efficacy and safety. As a dedicated educator, researcher, and leader, he has mentored future scientists while holding key academic positions. His impactful work continues to shape the future of pharmacological research and healthcare innovation. With numerous accolades and groundbreaking studies, his legacy will inspire generations to come, driving advancements in drug development and individualized therapy.

TOP NOTABLE PUBLICATIONS

Title: The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals

Authors: L. Wang, B. Yu, Y. Peng, H. Zhou, J. Yin

Journal: Innovation

Year: 2025

Title: Astragali Radix-Angelicae Sinensis Radix inhibits the activation of vascular adventitial fibroblasts and vascular intimal proliferation by regulating the TGF-β1/Smad2/3 pathway

Authors: W. Li, S. Xu, L. Chen, W. Zhang, C. Deng

Journal: Journal of Ethnopharmacology

Year: 2025

Title: Metabolic characteristics of saponins from Panax notoginseng leaves biotransformed by gut microbiota in rats

Authors: J. Liu, L. Shao, J. Zhou, W. Huang

Journal: Analytical Methods

Year: 2025

Title: Hypoglycemic Effect of Ginsenoside Compound K Mediated by N-Acetylserotonin Derived From Gut Microbiota

Authors: S.T.Z. Huang, Y.H. Hu, Y. Gao, W. Zhang, W. Huang

Journal: Phytotherapy Research

Year: 2025

Title: Antitumor potentials of onco-microbial in Chinese patients with pancreatic cancer

Authors: Y. Gao, D. Zhou, Y. Lu, W. Huang, W. Zhang

Journal: Heliyon

Year: 2024

Title: OSGEP regulates islet β-cell function by modulating proinsulin translation and maintaining ER stress homeostasis in mice

Authors: Y. Liu, X. Yang, J. Zhou, H. Zhou, Q. Li

Journal: Nature Communications

Year: 2024

Title: Promoting remyelination in central nervous system diseases: Potentials and prospects of natural products and herbal medicine

Authors: H. Zhu, E. Hu, X. Guo, Y. Wang, T. Li

Journal: Pharmacological Research

Year: 2024

Title: Formononetin alleviates no reflow after myocardial ischemia-reperfusion via modulation of gut microbiota to inhibit inflammation

Authors: Y. Zhang, J. Deng, T. Chen, Z. Guo, W. Zhang

Journal: Life Sciences

Year: 2024

Title: Mime: A flexible machine-learning framework to construct and visualize models for clinical characteristics prediction and feature selection

Authors: H. Liu, W. Zhang, Y. Zhang, S.Y. Wanggou, X. Li

Journal: Computational and Structural Biotechnology Journal

Year: 2024

QIU SUN | Vascular disease | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Mr. QIU SUN | Vascular disease | Best Researcher Award

Mr. QIU SUN, Heilongjiang University of Chinese Medicine, China

Mr. Qiu Sun is the Director of the Department, Chief Physician, Associate Professor, and a Ph.D. candidate at Heilongjiang University of Chinese Medicine, China. A recognized expert in Traditional Chinese Medicine (TCM), he is a National Academic Successor and policy advisor in TCM healthcare. He has led multiple research projects, published SCI-indexed papers, and contributed to national textbooks. With two invention patents and numerous awards, he plays a key role in TCM education, clinical practice, and policy-making. His work focuses on integrative medicine, vascular diseases, and external treatments, making a significant impact on TCM’s modernization and global recognition.

AUTHOR PROFILE

Scopus Profile

🎓 EARLY ACADEMIC PURSUITS:

Mr. Sun Qiu was born in June 1982 and pursued his medical education at Heilongjiang University of Chinese Medicine, graduating in June 2009. His academic journey in Traditional Chinese Medicine (TCM) was marked by dedication to both theoretical and clinical practice. Currently, he is a Ph.D. candidate, continuously expanding his expertise in integrative medicine while mentoring future medical professionals as a Master’s Supervisor.

🏥 PROFESSIONAL ENDEAVORS:

As the Director of the Department, Chief Physician, and Associate Professor, Sun Qiu plays a crucial role in shaping TCM medical practices. His extensive responsibilities include supervising medical teams, enhancing healthcare quality, and pioneering innovative treatment methodologies. His leadership has significantly contributed to policy development in TCM hospitals across Heilongjiang Province.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON VASCULAR DISEASE:

Mr. Sun Qiu has been actively involved in various high-impact research projects, including:

  • Principal Investigator for 1 provincial-level project, 3 department-level projects, and 2 university-level projects
  • Participant in a National Natural Science Foundation of China (NSFC) project
  • Published 2 SCI-indexed papers and over 20 other research papers
  • Editor, co-editor, or contributor to 8 published books, exceeding 700,000 words
  • Holds 2 invention patents, reflecting his innovative contributions to TCM

His research primarily focuses on integrated traditional Chinese and Western medicine surgery, vascular diseases, and external treatment techniques in TCM.

🌍 IMPACT AND INFLUENCE:

Mr. Sun Qiu’s influence extends beyond clinical practice into policy-making and education. His key roles include:

  • National Academic Successor of Key Clinical Specialties in TCM
  • Expert in the Traditional Chinese Medicine Policy Think Tank
  • National Expert for the Supervision of TCM Statistical Data Quality
  • Project Review Expert for Science and Technology Departments in Sichuan, Anhui, and Guangxi Provinces

His editorial contributions to the “14th Five-Year Plan” National Textbook showcase his commitment to shaping the future of TCM education.

📚 ACADEMIC CITES & JOURNAL CONTRIBUTIONS:

Mr. Sun Qiu is an esteemed peer reviewer for international and national journals, including:

  • Scientific Reports (UK)
  • BMC Gastroenterology
  • Clinical Epigenetics
  • Chinese Health Preservation
  • China Contemporary Medicine

His role as a reviewer ensures high-quality research in TCM and integrative medicine.

🏆 LEGACY AND FUTURE CONTRIBUTIONS:

Mr. Sun Qiu has received numerous prestigious awards, including:

  • Second Prize from the Heilongjiang Provincial Government
  • First Prize from the Heilongjiang Administration of Traditional Chinese Medicine
  • Advanced Individual of the National TCM Monitoring and Statistics Expert Advisory Committee
  • Outstanding Communist Party Member
  • Excellence in Teaching & Advanced Educator Awards

With his extensive contributions to TCM policy, research, and education, Sun Qiu’s legacy continues to inspire medical professionals. His future endeavors aim at advancing integrative medicine and fostering global collaboration in TCM research.

🌟 CONCLUSION:

Mr. Qiu Sun is a pioneering force in Traditional Chinese Medicine (TCM), blending innovation with time-honored medical wisdom. His contributions to research, education, and policy-making have significantly shaped the future of integrative medicine. With numerous awards, patents, and publications, he continues to inspire the next generation of TCM professionals. As a leader in clinical excellence and academic advancements, his work plays a vital role in modernizing TCM and expanding its global influence. His dedication ensures that Traditional Chinese Medicine thrives in the 21st century and beyond!

TOP NOTABLE PUBLICATION

The association between serum copper concentration and prevalence of diabetes among US adults with hypertension (NHANES 2011–2016)

Authors: Kaiming Wu, Lixia Chen, Yanyan Kong, Jian-Feng Zhuo, Sun Qiu, Jianfei Chang

Journal: Journal of Cellular and Molecular Medicine

Year: 2024

Dong MA | Cardiovascular Researches | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Prof. Dong MA | Cardiovascular Researches | Best Researcher Award

Prof. Dong MA, Hebei Medical University, China

Prof. Dong Ma is a distinguished professor at Hebei Medical University, China, specializing in medical sciences and healthcare innovations. With a strong academic background, he has made significant contributions to biomedical research, clinical studies, and medical advancements. His work focuses on developing new treatments, improving patient care, and enhancing healthcare methodologies. Prof. Ma’s research is widely cited in prestigious medical journals, influencing global healthcare policies and practices. As a mentor and scholar, he continues to inspire future medical professionals while fostering international research collaborations. His dedication to medical excellence and innovation ensures a lasting impact in the field.

AUTHOR PROFILE

Scopus Profile

🎓 EARLY ACADEMIC PURSUITS:

Prof. Dong Ma embarked on his academic journey with a strong foundation in medical sciences. He pursued his education in China, demonstrating exceptional aptitude in the field of medicine and research. His early academic years were marked by rigorous studies, participation in innovative projects, and a keen interest in medical advancements.

🏛️ PROFESSIONAL ENDEAVORS:

Prof. Ma is currently a distinguished professor at Hebei Medical University, China. Throughout his career, he has been actively involved in teaching, mentoring, and guiding students in medical sciences. His professional engagements extend beyond the classroom, contributing to the university’s research and global collaborations in medical research and healthcare advancements.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR RESEARCHES:

Prof. Ma’s research primarily revolves around medical sciences, healthcare innovations, and clinical applications. His work includes:

  • Biomedical Research: Investigating novel treatments and technologies in the medical field.
  • Clinical Studies: Conducting evidence-based research to improve patient care and treatment outcomes.
  • Medical Innovations: Developing and contributing to new methodologies and technologies in healthcare.

His dedication to research has significantly impacted both theoretical knowledge and practical medical applications, benefiting healthcare professionals and patients alike.

🌍 IMPACT AND INFLUENCE:

Prof. Ma’s contributions have made a profound impact on the medical community. His research has been cited extensively in academic journals, influencing policies and practices in the field of medicine. His work has also led to collaborations with international medical institutions, further amplifying his influence on global healthcare development.

📖 ACADEMIC CITATIONS:

Prof. Ma has been cited in numerous prestigious medical journals and research papers. His publications cover a wide range of topics, including:

  • Advances in medical treatments and techniques.
  • Healthcare policy improvements.
  • Breakthroughs in disease prevention and management.

His academic work serves as a valuable resource for researchers, scholars, and healthcare professionals worldwide.

🏅 LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Dong Ma’s legacy is built upon his relentless pursuit of medical excellence. His future contributions are expected to:

  • Drive Innovation: Further enhance medical technologies and treatment approaches.
  • Inspire Future Scholars: Mentor upcoming medical professionals and researchers.
  • Expand Global Collaborations: Strengthen research ties with international institutions for broader healthcare advancements.

🔥 CONCLUSION:

Prof. Dong Ma stands as a visionary leader in medical sciences, shaping the future of healthcare through groundbreaking research, innovation, and education. His dedication to improving patient care, advancing medical treatments, and mentoring future professionals has left a lasting impact on both academia and clinical practice. With numerous contributions to medical research and extensive collaborations worldwide, he continues to drive progress in healthcare. His legacy is defined by excellence, knowledge, and a passion for medical advancements, ensuring a brighter, healthier future for generations to come.

TOP NOTABLE PUBLICATIONS

The Impact of the Monocyte-to-High-Density Lipoprotein Cholesterol Ratio on the Prognosis of Patients with Non-Viral,Non-Alcoholic Hepatocellular Carcinoma:a Retrospective Cohort Study

Authors: Xianzhe Lou, Tongguo Miao, Shiya Zhang, Dong Ma, Yuemin Nan

Journal: Chinese General Practice

Year: 2025

Combined DeRitis ratio and alkaline phosphatase on the prediction of portal vein tumor thrombosis in patients with hepatocellular carcinoma

Authors: Tongguo Miao, Shiya Zhang, Yunjing Zhang, Dong Ma, Yuemin Nan

Journal: Scientific Reports

Year: 2024

Study on the relationship between Methylation of Neuregulin (NRG) Gene and Cervical Carcinoma

Authors: Xizhao Yan, Fenglan An, Zhenzhen Ding, Dong Ma, Xiaohui Yang

Journal: Pakistan Journal of Medical Sciences

Year: 2024

α-HBDH is a superior to LDH in predicting major adverse cardiovascular events in patients with acute aortic dissection

Authors: Yunjing Zhang, Yue Sun, Yongbo Zhao, Dong Ma

Journal: Heliyon

Year: 2024

Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease

Authors: Tongguo Miao, Xianzhe Lou, Shiming Dong, Dong Ma, Yuemin Nan

Journal: Journal of Hepatocellular Carcinoma

Year: 2024

Boyoung Park | Epidemiology | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Prof. Boyoung Park | Epidemiology | Best Researcher Award

Prof. Boyoung Park, Hanyang University College of Medicine, South Korea

Professor Boyoung Park is a distinguished expert in preventive medicine, currently serving at Hanyang University College of Medicine in Seoul, South Korea. She leads the Bio-Big Data Center at the Hanyang Institute of Bioscience and Biotechnology. Her research, focusing on breast cancer risk factors and epidemiology, has been published in reputable journals such as the British Journal of Cancer and BMJ Open. In 2023, she was honored with the Kwangdong Cancer Academic Award by the Korean Cancer Association. Additionally, she contributes to the academic community as a senior editor for the Journal of Preventive Medicine & Public Health.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

🎓 EARLY ACADEMIC PURSUITS:

Professor Boyoung Park embarked on her medical education at the Catholic University of Daegu, where she earned her M.D. in 2006. Her passion for preventive medicine led her to Seoul National University College of Medicine, where she obtained her M.S. in 2010 and subsequently completed her Ph.D. in 2012. This strong academic foundation set the stage for her future contributions to epidemiology and cancer research.

💼 PROFESSIONAL ENDEAVORS:

Prof. Park’s career trajectory has been marked by prestigious positions in both academia and research institutions:

  • Director of the Bio-BigData Center at the Hanyang Institute of Bioscience and Biotechnology (2024–present)
  • Professor at the Department of Preventive Medicine, Hanyang University College of Medicine (2023–present)
  • Associate Professor at Hanyang University College of Medicine (2018–2023)
  • Assistant Professor at the National Cancer Center Graduate School of Cancer Science and Policy (2015–2018)
  • Associate Scientist at the National Cancer Control Institute, National Cancer Center (2012–2018)
  • Fellowship at the National Cancer Control Institute, National Cancer Center (2011–2012)
  • Residency in Preventive Medicine at Seoul National University College of Medicine (2008–2011)
  • Internship at Asan Medical Center, Seoul (2006–2007)

Her experience spans clinical practice, research, and academic leadership, demonstrating her commitment to advancing public health and epidemiology.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON EPIDEMIOLOGY:

Prof. Park has played a crucial role in cancer epidemiology, HIV research, and the development of disease risk assessment models. Her research interests include:

  • Cancer prevention and control
  • HIV/AIDS and chronic infectious diseases
  • Big data and epidemiological studies
  • Genome analysis and risk assessment models

🏆 RESEARCH GRANTS:

She has led multiple nationally funded projects, including:

  • Korea HIV/AIDS Cohort Study (2023–2024) – Principal Investigator
  • Korea Atomic Bomb Survivors Cohort and Genome Analysis (2020–2024) – Principal Investigator
  • Development of a Breast Cancer Risk Assessment Model (2021–2025) – Principal Investigator
  • Transfusion and Prognosis in Hepatobiliary & Pancreatic Surgery (2022–2025) – Principal Investigator

🏅 IMPACT AND INFLUENCE:

Prof. Park’s work has been widely recognized through prestigious awards and honors, such as:

  • National AIDS and STI Contributor Award (2023) – Korea Disease Control and Prevention Agency
  • Kwangdong Cancer Academic Award (2023) – Korean Cancer Association
  • Outstanding Paper Review Committee Award (2022) – Korean Society of Epidemiology
  • Excellent Researcher Award (2021) – Hanyang University
  • Young Epidemiologist Award (2015) – Korean Society of Epidemiology

📖 ACADEMIC CITATIONS AND EDITORIAL CONTRIBUTIONS:

Prof. Park serves as a Senior Editor and Editorial Board Member for leading medical journals:

  • Journal of Preventive Medicine & Public Health (Senior Editor)
  • Cancer Research and Treatment (Editorial Board Member)
  • Journal of Cancer Prevention (Editorial Board Member)

Her contributions to medical literature have significantly shaped the fields of epidemiology and public health.

🔮 LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Boyoung Park has established herself as a leading figure in preventive medicine and cancer epidemiology. Moving forward, she aims to:
 Advance big data-driven epidemiological research
Enhance public health policies for cancer prevention
Develop personalized risk assessment models for chronic diseases
Strengthen national and global health collaborations

Her groundbreaking work continues to shape the future of epidemiology, public health, and medical research in South Korea and beyond.

🌍CONCLUSION:

Professor Boyoung Park has made significant contributions to preventive medicine, epidemiology, and cancer research. As the Director of the Bio-Big Data Center at Hanyang University, her work in breast cancer risk assessment and public health continues to shape medical advancements. Recognized with prestigious awards, including the Kwangdong Cancer Academic Award, she remains a leading figure in medical research. Through her editorial roles and government advisory positions, she influences healthcare policies and scientific discourse. Her legacy will inspire future researchers and improve global public health outcomes.

TOP NOTABLE PUBLICATIONS

Economic Evaluation of Mass Screening as a Strategy for Hepatitis C Virus Elimination in South Korea

Authors: Hwa-young Choi, Kyung-ah Kim, Boyoung Park, Bo-youl Choi, Moran Ki

Journal: Journal of Infection and Public Health

Year: 2025

Korean Patients with Hereditary Cancer: A Prospective Multicentre Cohort Study Protocol Exploring Psychosocial and Health Outcomes

Authors: Jun-kyu Kim, Mi-Ae Jang, Jong-eun Park, Boyoung Park, Sun-young Kong

Journal: BMJ Open

Year: 2025

Associations Between Breastfeeding and Breast Cancer Risk Through Mammographic Breast Density in a Cohort of Korean Women

Authors: Soyeoun Kim, Thi Xuan Mai Tran, Mi-kyung Kim, Woojoo Lee, Boyoung Park

Journal: International Journal of Epidemiology

Year: 2025

Concordant and Discordant Breast Density Patterns by Different Approaches for Assessing Breast Density and Breast Cancer Risk

Authors: Yoosun Cho, Eunkyung Park, Yoosoo Chang, Shinho Kook, Seungho Ryu

Journal: Breast Cancer Research and Treatment

Year: 2025

A National Estimate of Mental Disorders and Mortality Outcomes in Cancer Survivors

Authors: Thi Xuan Mai Tran, Minsung Chung, Boyoung Park

Journal: Cancer

Year: 2025

Refining Breast Cancer Genetic Risk and Biology Through Multi-Ancestry Fine-Mapping Analyses of 192 Risk Regions

Authors: Guochong Jia, Zhishan Chen, Jie Ping, Jirong Long, Wei Zheng

Journal: Nature Genetics

Year: 2025

Carrier Frequency and Incidence of MUTYH-Associated Polyposis Based on Database Analysis in East Asians and Koreans

Authors: Jong-eun Park, Taeheon Lee, Eun-hye Cho, Chang-Seok Ki, Sun-young Kong

Journal: Annals of Laboratory Medicine

Year: 2025

Correction to: Height and Breast Cancer Risk in Premenopausal Korean Women Aged Under 40 Years of Age

Authors: Thi Xuan Mai Tran, Yoosoo Chang, Hye-rin Choi, Seungho Ryu, Boyoung Park

Journal: British Journal of Cancer

Year: 2024

Height and Breast Cancer Risk in Premenopausal Korean Women Aged Under 40 Years of Age: Epidemiology

Authors: Thi Xuan Mai Tran, Yoosoo Chang, Hye-rin Choi, Seungho Ryu, Boyoung Park

Journal: British Journal of Cancer

Year: 2024

Epidemiological Characteristics of HIV-Infected Individuals by the Registration for Special Exempted Calculation: A Nationwide Cohort Study

Authors: Yunsu Choi, Kyoung-hwan Ahn, Soomin Kim, Yoonhee Jun, Boyoung Park

Journal: Infection and Chemotherapy

Year: 2024

Zhihui Zhang | Cardiovascular Research | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Prof. Zhihui Zhang | Cardiovascular Research | Best Researcher Award

Prof. Zhihui Zhang, Army Medical University, China

Prof. Zhihui Zhang is a distinguished researcher at Army Medical University, China, specializing in cardiovascular diseases and stem cell therapy. His work focuses on endothelial seed cells, myocardial infarction, and immunosuppressive capabilities of mesenchymal stem cell-derived extracellular vesicles. He has published extensively in leading journals such as Genes and Diseases, Science Bulletin, and Stem Cell Research and Therapy. Prof. Zhang’s research contributes to advancing early diagnosis and targeted interventions for coronary microvascular dysfunction. His expertise in molecular biology and regenerative medicine has made significant impacts in cardiovascular research and clinical applications.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Zhihui Zhang embarked on his academic journey with a deep passion for cardiovascular medicine. His early education laid a strong foundation in medical sciences, leading him to specialize in cardiology. His dedication and excellence in research and clinical practice positioned him for advanced studies and significant contributions to the field.

🏥PROFESSIONAL ENDEAVORS:

Dr. Zhang is the Director of the Department of Cardiology at the First Affiliated Hospital (Southwest Hospital) of the Army Medical University in Chongqing. His leadership extends beyond the hospital as he holds multiple prestigious roles:

  • Member of the Great Vessel Group under the Cardiology Branch of the Chinese Medical Association
  • Member of the Cardiologists’ Association of the Chinese Medical Doctor Association
  • Deputy Director of the Committee for Structural Heart Disease under the China Human Health Promotion Association
  • Deputy Director of the Cardiology Branch of the Chongqing Medical Association, leading the Interventional Cardiology and Imaging Group

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR RESEARCH:

Dr. Zhang is renowned for his expertise in interventional treatment of coronary heart disease and structural heart disease. His research focuses on:

  • Precise diagnosis and treatment of coronary heart disease
  • Interventional therapy for valvular heart diseases
  • Establishing a cohort for precise classification of myocardial ischemia
  • Creating a biobank and an artificial intelligence center for coronary angiography physiological assessment

Additionally, he has developed the professional Circa Met DB database, specializing in metabolic circadian rhythms.

🌍IMPACT AND INFLUENCE:

Dr. Zhang’s contributions have earned him numerous accolades, including:
🏆 Two first prizes for scientific progress in Chongqing
🏆 One first prize for scientific progress in Hubei Province
🏆 One second prize for military medical achievements

He has successfully led over 20 research projects, ranging from national natural science funds to key military and Chongqing talent programs. His pioneering work in cardiology has influenced national and military healthcare policies.

📖ACADEMIC CITATIONS:

Dr. Zhang has an outstanding publication record, with more than 30 SCI papers as the first or corresponding author (including co-first/co-corresponding). His research has been featured in top-tier journals such as:
📌 The Lancet
📌 Nature Metabolism
📌 Nature Communications
📌 Trends in Cell Biology

Additionally, he has contributed to drafting and setting 12 expert consensus documents, served as a deputy editor for two monographs, and contributed to nine other books. His work extends to two national invention patents, further solidifying his impact in the field.

🚀LEGACY AND FUTURE CONTRIBUTIONS:

As a recipient of the Outstanding Youth Talent Fund in National Defense Bioscience, Dr. Zhang is recognized as a key innovator in cardiology. He has been honored as an Innovation Leading Talent by the Chongqing Talents Program and as a Science and Technology Talent by the Army.

His legacy will continue to shape the future of cardiovascular medicine through:
✅ Advanced research in interventional cardiology
✅ Expansion of AI-driven medical diagnostics
✅ Development of groundbreaking therapeutic techniques
✅ Mentorship and training of future cardiologists

🌟CONCLUSION:

Prof. Zhihui Zhang is a visionary leader in cardiology, blending clinical excellence, groundbreaking research, and technological innovation. His contributions have not only transformed patient care but also advanced global medical knowledge. His work will undoubtedly influence generations of medical professionals and redefine the future of cardiovascular treatment.

TOP NOTABLE PUBLICATIONS

Single nucleotide polymorphisms: Implications in the early diagnosis and targeted intervention of coronary microvascular dysfunction

Authors: Dingyuan Tian, Jie Li, Qingyuan Yang, Zhihui Zhang, Fang Deng

Journal: Genes and Diseases

Year: 2025

Circadian nutrition: is meal timing an elixir for fatigue?

Authors: Zhihui Zhang, Lu Yan, Jonas T. Treebak, Min-Dian Li

Journal: Science Bulletin

Year: 2025

Foxo1 drives the TGFβ1-dependent dichotomy of Th17 cell fates

Authors: Mengjuan Zhang, Yude Guan, Meijuan Han, Xiaomin Zhang, Song Zhang

Journal: Journal of Leukocyte Biology

Year: 2025

The short-term outcomes and risk factors of post-myocardial infarction ventricular septal rupture: a multi-center retrospective study

Authors: Wenjian Luo, Li Wen, Jinning Zhang, Zhexue Qin, Shiyong Yu

Journal: Journal of Cardiothoracic Surgery

Year: 2024

Sources and applications of endothelial seed cells: a review

Authors: Dan Deng, Yu Zhang, Bo Tang, Zhihui Zhang

Journal: Stem Cell Research and Therapy

Year: 2024

Enhanced immunosuppressive capability of mesenchymal stem cell-derived small extracellular vesicles with high expression of CD73 in experimental autoimmune uveitis

Authors: Yanan Duan, Xiteng Chen, Hui Shao, Jiawei Wang, Xiaomin Zhang

Journal: Stem Cell Research and Therapy

Year: 2024

Deciphering metabolic heterogeneity in retinoblastoma unravels the role of monocarboxylate transporter 1 in tumor progression

Authors: Junjie Tang, Yaoming Liu, Yinghao Wang, Ping Zhang, Rong Lu

Journal: Biomarker Research

Year: 2024

Associations between non-insulin-based insulin resistance indices and heart failure prevalence in overweight/obesity adults without diabetes mellitus: evidence from the NHANES 2001–2018

Authors: Diyu Cui, Chao Zhang, Yi Chen, Yu Zhang, Ping Zhu

Journal: Lipids in Health and Disease

Year: 2024

Single-cell transcriptomics enable the characterization of local extension in retinoblastoma

Authors: Yaoming Liu, Wei Hu, Yanjie Xie, Shengli Li, Rong Lu

Journal: Communications Biology

Year: 2024

Clinical characteristics of patients with moderate or severe valvular heart disease

Authors: Hao Gao, Yuzhu Lei, Haiyun Huang, Yanxiu Chen, Zhihui Zhang

Journal: Chinese Journal of Cardiology

Year: 2024

Yan Zhang | Cardiovascular diseases | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Prof. Yan Zhang | Cardiovascular diseases | Best Researcher Award 

Prof. Yan Zhang, Affiliated Hospital,Liaoning University of Traditional Chinese Medicine, China

Prof. Yan Zhang is a distinguished researcher and medical expert at the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, China. With extensive experience in Traditional Chinese Medicine (TCM), her research focuses on integrative medicine, herbal formulations, and their clinical applications. She has contributed significantly to the advancement of TCM through numerous publications and collaborative projects. Prof. Zhang is dedicated to bridging modern medical practices with ancient healing traditions, enhancing patient care and treatment efficacy. Her work plays a crucial role in promoting evidence-based TCM approaches for various health conditions, fostering innovation in holistic healthcare solutions.

AUTHOR PROFILE

Scopus Profile

✨ EARLY ACADEMIC PURSUITS:

Prof. Yan Zhang embarked on an illustrious academic journey in Traditional Chinese Medicine (TCM). His foundational education began at Liaoning College of Traditional Chinese Medicine, where he earned a Bachelor’s Degree in Traditional Chinese Medicine (1978-1983). His keen interest in advancing his expertise led him to pursue a Master’s Degree in Typhoid Fever (1986-1989) from the same institution. Determined to further his knowledge, he obtained a Ph.D. in Internal Medicine (2001-2004) from Beijing University of Chinese Medicine, one of China’s most prestigious institutions for TCM studies.

👩‍🎓 PROFESSIONAL ENDEAVORS:

Prof. Zhang’s professional career spans over four decades, marked by dedication and leadership. His significant roles include:

  • Chief Physician (Since 2012): He has been leading the Cardiopulmonary Department at the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine.
  • Director of the Department of Research (2006-2012): At the same hospital, he oversaw groundbreaking medical research and contributed to numerous advancements in TCM.
  • Director of Internal Medicine (1989-2001): He served as the Director of the Department of Traditional Chinese Medicine Internal Medicine at the Liaoning College of Traditional Chinese Medicine Affiliated Hospital.
  • Early Medical Practice (1983-1986): His career began as a Doctor in the Department of Internal Medicine at Dandong City Traditional Chinese Medicine Hospital.

📚 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR DISEASES:

Prof. Zhang is a pioneer in Traditional Chinese Medicine, with a specialized focus on cardiovascular diseases. His research revolves around integrating modern medical techniques with traditional healing practices, making significant strides in the treatment of cardiopulmonary disorders. As an academic leader of China’s national key discipline for cardiovascular research, he has spearheaded numerous studies and projects that have influenced the field profoundly.

He is an expert evaluator for major scientific organizations, including:

  • China’s National Natural Science Foundation Projects
  • China’s National Science and Technology Awards

His contributions have been instrumental in shaping national policies and advancements in TCM research.

🌟 IMPACT AND INFLUENCE:

Prof. Zhang’s influence extends beyond his hospital and university. His expertise has earned him several prestigious accolades, including:

  • Renowned Traditional Chinese Medicine Practitioner of Liaoning Province
  • Outstanding Talent & Expert of Liaoning Province
  • Advanced Scientific and Technological Worker in Liaoning Province
  • Recipient of the Special Allowance of the State Council of China

His mentorship has nurtured numerous doctoral candidates, ensuring that the future of Traditional Chinese Medicine remains in capable hands.

📚 ACADEMIC CITES:

Prof. Zhang’s extensive research and scholarly contributions have been widely cited in various national and international medical journals. His work on cardiovascular health, herbal medicine formulations, and the integration of TCM with modern science has set a benchmark for medical professionals worldwide.

🌟 LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Zhang’s legacy in Traditional Chinese Medicine is monumental. His future contributions aim to:

  • Develop new treatment methodologies that combine Western and Eastern medical practices.
  • Mentor the next generation of TCM practitioners.
  • Influence government health policies for the wider acceptance of TCM in mainstream healthcare.
  • Continue his groundbreaking research on cardiovascular diseases.

As a visionary leader in Traditional Chinese Medicine, Prof. Yan Zhang’s dedication, research, and teachings will continue to shape the medical landscape for generations to come.

✨CONCLUSION:

Prof. Yan Zhang’s dedication to Traditional Chinese Medicine (TCM) continues to shape the future of integrative healthcare. Through her research, clinical expertise, and innovative approaches, she bridges ancient wisdom with modern medical advancements, ensuring better patient outcomes . Her contributions not only enhance TCM’s credibility worldwide but also inspire future generations of practitioners and researchers. With a passion for holistic healing and evidence-based medicine, Prof. Zhang remains a key figure in promoting natural therapies for global health and wellness. Her work stands as a testament to the enduring power of TCM in modern medicine.

TOP NOTABLE PUBLICATION

Mechanism of Ferroptosis in Regulating Chronic Heart Failure and Traditional Chinese Medicine Prevention and Treatment Based on Qi Deficiency and Stagnation: A Review

Journal: Chinese Journal of Experimental Traditional Medical Formulae
Year: 2025

Ruping Dai | Cardiovascular Anesthesia | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Prof. Dr. Ruping Dai | Cardiovascular Anesthesia | Best Researcher Award 

Prof. Dr.  Ruping Dai, Second Xiangya Hospital, China

Prof. Dr. Ruping Dai is the Director of Anesthesiology at the Second Xiangya Hospital, Central South University, China. He earned his Ph.D. in Clinical Medicine from the National University of Singapore in 2004 and completed postdoctoral research at the Institute of Molecular and Cell Biology, Singapore. Prof. Dai specializes in clinical anesthesia, pain management, intensive care, perioperative medicine, and organ protection. He has led four projects funded by the National Natural Science Foundation of China and has published 24 SCI papers. His accolades include the New Century Talent Support Program (2012) and the Hunan Province Outstanding Youth Fund (2013).

AUTHOR PROFILE

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Dr. Ruping Dai embarked on his academic journey at the Xiangya School of Medicine, Central South University, where he earned his Bachelor’s degree in Anesthesiology (1993-1998). His thirst for knowledge led him to pursue a Ph.D. in Medicine at the National University of Singapore (2000-2004), where he focused on advanced medical research. He further honed his expertise as a Postdoctoral Fellow at the National Institute of Molecular and Cell Biology, Singapore (2004-2006), gaining in-depth knowledge in molecular and cellular biology applications in anesthesiology.

🏥PROFESSIONAL ENDEAVORS:

Dr. Dai began his career in the Department of Cardiothoracic Surgery, Union Hospital Affiliated to Fujian Medical University (1998-2000), specializing in cardiovascular anesthesia and intensive care. Since October 2006, he has been a Chief Physician and Doctoral Supervisor at the Department of Anesthesiology, Second Xiangya Hospital, Central South University. Over the years, he has played a vital role in clinical anesthesia and Anesthesia Intensive Care Units (AICU), ensuring excellence in patient care and medical education.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR ANESTHESIA:

Dr. Dai’s research primarily focuses on anesthesiology, organ protection, perioperative care, and immunosuppression mechanisms in sepsis. He has led multiple groundbreaking studies on topics such as:

  • Postoperative sepsis mechanisms
  • Perioperative acute lung injury
  • Neuroplasticity and postoperative cognitive dysfunction (POCD)
  • Microglial/macrophage polarization in spinal cord ischemia-reperfusion injury

Dr. Dai has hosted 7 National Natural Science Foundation (NSFC) projects, receiving significant research funding, including:

  • Key Project on Hematogenous Macrophage Role in Postoperative Sepsis (2025-2028) – RMB 2.6 million
  • SIRT5-Mitochondrial Metabolic Axis in Perioperative Acute Lung Injury (2024-2027) – RMB 490,000
  • Macrophage Dysfunction in Sepsis Immunosuppression (2021-2024) – RMB 560,000
  • Microglia Polarization in Spinal Cord Ischemia-Reperfusion Injury (2018-2021) – RMB 540,000

🌍IMPACT AND INFLUENCE:

Dr. Dai holds several prestigious administrative positions, including:

  • Director of Anesthesiology, Second Xiangya Hospital, Central South University
  • Director, Institute of Anesthesiology, Central South University
  • Director, Hunan Anesthesia Clinical Medicine Research Center
  • Director, Hunan Provincial Organ Damage Prevention and Treatment Engineering Center

In academia, he serves as:

  • Deputy Chairman, Hunan Provincial Anesthesiology Committee
  • National Committee Member, Anesthesiology Branch, Chinese Medical Doctor Association
  • Vice Chairman, 13th Youth Committee of the Chinese Medical Association Anesthesiology Branch
  • Deputy Director, Orthopedics Group, Chinese Medical Association Anesthesiology Branch
  • Standing Committee Member, Cardiovascular Anesthesia Branch, Chinese Society of Thoracic and Cardiovascular Anesthesiology

📖ACADEMIC CITES AND SCHOLARLY CONTRIBUTIONS:

Dr. Dai has played a crucial role in education, having authored and co-edited several key textbooks:

  1. Clinical Anesthesiology (First Editor, Science Press, 14th Five-Year Plan)
  2. Postgraduate Textbook: Anesthesiology (Selected Topics of Basic Anesthesia Research, People’s Medical Publishing House, 2014)
  3. Resident Medical Planning Textbook: Anesthesiology (Postoperative Acute Pain Management, People’s Medical Publishing House, 2014)
  4. Co-translator of Miller’s Anesthesiology (7th & 8th editions, Opioids section, 2017)

🏆SCIENCE AND TECHNOLOGY AWARDS:

Dr. Dai’s excellence in research and innovation has earned him several prestigious awards, including:

  • Second Prize of Hunan Natural Science Award (2019)
  • Third “Light of Spirit” Excellent Youth Research Fund – Second Prize
  • Award-winning fund for Young and Middle-aged Excellent Paper Competition at the Chinese Anesthesia Annual Meeting

🔮LEGACY AND FUTURE CONTRIBUTIONS:

As a pioneering figure in anesthesiology, Dr. Dai continues to shape the future of perioperative medicine, critical care, and pain management. His leadership in cutting-edge research, education, and healthcare innovation ensures his lasting impact in the field. Through mentorship and research, he remains dedicated to improving patient outcomes and advancing medical science, setting a benchmark for future anesthesiologists worldwide.

🌟CONCLUSION:

Prof. Dr. Ru-Ping Dai is a distinguished anesthesiologist and researcher at the Second Xiangya Hospital, Central South University, China. As the Director of the Department of Anesthesiology, he has significantly advanced perioperative medicine, focusing on neuroimmune interactions and organ protection. His notable work includes elucidating the roles of brain-derived neurotrophic factor (BDNF) and its precursor, pro-BDNF, in mood disorders, offering new perspectives on neuroimmune crosstalk. Prof. Dai’s dedication to integrating clinical practice with research has enhanced patient care and contributed to the global medical community’s understanding of anesthesiology and neuroscience.

TOP NOTABLE PUBLICATIONS

Brain derived neurotrophic factor (BDNF) contributes to the pain hypersensitivity following surgical incision in the rats

Authors: CQ Li, JM Xu, D Liu, JY Zhang, RP Dai
Journal: Molecular Pain
Year: 2008

Local translation and retrograde axonal transport of CREB regulates IL-6-induced nociceptive plasticity

Authors: OK Melemedjian, DV Tillu, JK Moy, MN Asiedu, EK Mandell, S Ghosh, …
Journal: Molecular Pain
Year: 2014

Early-life social isolation-induced depressive-like behavior in rats results in microglial activation and neuronal histone methylation that are mitigated by minocycline

Authors: HT Wang, FL Huang, ZL Hu, WJ Zhang, XQ Qiao, YQ Huang, RP Dai, F Li, …
Journal: Neurotoxicity Research
Year: 2017

Histone 2B (H2B) expression is confined to a proper NAD+/NADH redox status

Authors: RP Dai, FX Yu, SR Goh, HW Chng, YL Tan, JL Fu, L Zheng, Y Luo
Journal: Journal of Biological Chemistry
Year: 2008

Effects of down-regulation of microRNA-23a on TNF-α-induced endothelial cell apoptosis through caspase-dependent pathways

Authors: W Ruan, J Xu, S Li, L Yuan, R Dai
Journal: Cardiovascular Research
Year: 2012

Development of anxiety-like behavior via hippocampal IGF-2 signaling in the offspring of parental morphine exposure: effect of enriched environment

Authors: CQ Li, YW Luo, FF Bi, TT Cui, L Song, WY Cao, JY Zhang, F Li, JM Xu, …
Journal: Neuropsychopharmacology
Year: 2014

Dexmedetomidine reduces the incidence of fentanyl-induced cough: a double-blind, randomized, and placebo-controlled study

Authors: L He, JM Xu, RP Dai
Journal: Upsala Journal of Medical Sciences
Year: 2012

Adipocyte fatty acid-binding protein promotes palmitate-induced mitochondrial dysfunction and apoptosis in macrophages

Authors: H Li, Y Xiao, L Tang, F Zhong, G Huang, JM Xu, AM Xu, RP Dai, ZG Zhou
Journal: Frontiers in Immunology
Year: 2018

Insulin-like growth factor 2 mitigates depressive behavior in a rat model of chronic stress

Authors: YW Luo, Y Xu, WY Cao, XL Zhong, J Duan, XQ Wang, ZL Hu, F Li, …
Journal: Neuropharmacology
Year: 2015

Biphasic activation of extracellular signal-regulated kinase in anterior cingulate cortex distinctly regulates the development of pain-related anxiety and mechanical …

Authors: RP Dai, CQ Li, JW Zhang, F Li, XD Shi, JY Zhang, XF Zhou
Journal: Anesthesiology
Year: 2011

Zhuofeng Lin | Myocardial infarction | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Prof. Dr. Zhuofeng Lin | Myocardial infarction | Best Researcher Award 

Prof. Dr. Zhuofeng Lin, Guangdong Medical University, China

Prof. Dr. Zhuofeng Lin is the Dean of the Experimental Animal Center and Dean of the Innovational Center of Cardiometabolic Disease at Guangdong Medical University, China. His research focuses on cross-organ communication in cardiovascular and metabolic diseases, particularly the role of metabolic hormones and obesity. He has made significant contributions to understanding FGF21 metabolic regulation, impacting blood glucose stability, blood pressure control, and anti-atherosclerosis therapies. His work also explores new targets for anti-myocardial infarction, heart failure, and vascular calcification drugs, driving innovation in metabolic and cardiovascular medicine. His research is widely recognized in international medical science.

AUTHOR PROFILE

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Dr. Zhuofeng Lin’s academic journey began with a strong foundation in medical sciences, focusing on cardiovascular and metabolic diseases. His early research explored physiological mechanisms and metabolic interactions, leading him to specialize in cross-organ communication and metabolic regulation. His education and initial training laid the groundwork for his extensive contributions to cardiometabolic research.

🏢PROFESSIONAL ENDEAVORS:

Prof. Lin has held prestigious positions at Guangdong Medical University, where he currently serves as:

  • Dean of the Experimental Animal Center 🐁
  • Dean of the Innovational Center of Cardiometabolic Disease 🫀

His leadership in these institutions has driven significant advancements in experimental research methodologies and the development of innovative treatment strategies for metabolic disorders.

🔍CONTRIBUTIONS AND RESEARCH FOCUS ON MYOCARDIAL INFARCTION:

Prof. Lin’s research is dedicated to practical applications, with a strong emphasis on:

  • Cross-organ communication in cardiovascular and metabolic diseases
  • Pathogenesis of cardiometabolic disorders linked to metabolic hormones and obesity
  • Fibroblast Growth Factor 21 (FGF21) and its role in metabolic regulation

His studies have provided groundbreaking insights into FGF21’s ability to regulate:
✅ Blood glucose levels
✅ Blood pressure stability
✅ Anti-atherosclerosis mechanisms
✅ Anti-Metabolic Dysfunction-Associated Steatohepatitis (MASH) therapies

Additionally, his work focuses on discovering new therapeutic targets for:
⚕️ Anti-myocardial infarction drugs
⚕️ Anti-heart failure treatments
⚕️ Anti-vascular calcification solutions

🌍IMPACT AND INFLUENCE:

Prof. Lin’s research has had a profound impact on global medical science, particularly in the fields of:
🔹 Metabolic disease management
🔹 Cardiovascular treatment innovations
🔹 Therapeutic drug development

His studies have influenced clinical practices, contributing to better patient outcomes in cardiovascular and metabolic health. His pioneering work in hormonal regulation and metabolic stability has inspired numerous scientists and researchers worldwide.

📄ACADEMIC CITES AND RECOGNITION:

Prof. Lin’s research is widely recognized in high-impact medical journals, with numerous citations supporting his theories. His work on FGF21 metabolic regulation is frequently referenced in the fields of endocrinology, cardiology, and metabolic research. He has been a keynote speaker at international medical conferences, sharing his insights with the global scientific community.

🚀LEGACY AND FUTURE CONTRIBUTIONS:

With an unwavering commitment to scientific innovation, Prof. Lin continues to shape the future of medical research. His ongoing projects aim to:
🔬 Develop novel cardiometabolic therapies
🔬 Enhance cross-organ communication research
🔬 Introduce cutting-edge treatments for heart disease and metabolic disorders

His legacy will be defined by his transformative contributions to medicine, paving the way for future breakthroughs in cardiovascular and metabolic health.

💡CONCLUSION:

Prof. Dr. Zhuofeng Lin is a pioneering leader in cardiometabolic research, making groundbreaking contributions to understanding metabolic regulation and cardiovascular health. His work on FGF21 has revolutionized approaches to blood glucose stability, blood pressure control, and anti-atherosclerosis treatments . With a vision for therapeutic innovation, he continues to explore new drug targets for heart failure, myocardial infarction, and vascular calcification . His impact on medical science is profound, shaping the future of metabolic and cardiovascular treatments. His dedication ensures lasting advancements in healthcare and patient well-being.

TOP NOTABLE PUBLICATIONS

Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice

Authors: Z Lin, H Tian, KSL Lam, S Lin, RCL Hoo, M Konishi, N Itoh, Y Wang, …
Journal: Cell Metabolism
Year: 2013

Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice

Authors: Z Lin, X Pan, F Wu, D Ye, Y Zhang, Y Wang, L Jin, Q Lian, Y Huang, …
Journal: Circulation
Year: 2015

Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile

Authors: Z Lin, Z Wu, X Yin, Y Liu, X Yan, S Lin, J Xiao, X Wang, W Feng, X Li
Journal: PLoS One
Year: 2010

Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues

Authors: L Geng, B Liao, L Jin, Z Huang, CR Triggle, H Ding, J Zhang, Y Huang, …
Journal: Cell Reports
Year: 2019

Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2

Authors: D Ye, K Yang, S Zang, Z Lin, HT Chau, Y Wang, J Zhang, J Shi, A Xu, …
Journal: Journal of Hepatology
Year: 2016

Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese

Authors: Z Lin, Z Zhou, Y Liu, Q Gong, X Yan, J Xiao, X Wang, S Lin, W Feng, X Li
Journal: PLoS One
Year: 2011

FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1–7) axis in mice

Authors: X Pan, Y Shao, F Wu, Y Wang, R Xiong, J Zheng, H Tian, B Wang, …
Journal: Cell Metabolism
Year: 2018

Adiponectin protects against acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice

Authors: Z Lin, F Wu, S Lin, X Pan, L Jin, T Lu, L Shi, Y Wang, A Xu, X Li
Journal: Journal of Hepatology
Year: 2014

Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling‐dependent manner

Authors: Y Pan, B Wang, J Zheng, R Xiong, Z Fan, Y Ye, S Zhang, Q Li, F Gong, …
Journal: Journal of Cellular and Molecular Medicine
Year: 2019

Dynamic change of serum FGF21 levels in response to glucose challenge in human

Authors: Z Lin, Q Gong, C Wu, J Yu, T Lu, X Pan, S Lin, X Li
Journal: The Journal of Clinical Endocrinology & Metabolism
Year: 2012